EGFR and non-small cell lung carcinoma: Osimertinib was the first third‐generation EGFR‐TKI approved for first‐line treatment in NSCLC patients harboring common EGFR mutations, receiving regulatory approval in multiple countries, including those in the European Union [11] and the United States [12, 13].